43 results
F-3
SCNI
Scinai Immunotherapeutics Ltd
30 Jan 24
Shelf registration (foreign)
4:19pm
, the content of applicable U.S. law must be proved as a fact by expert witnesses which can be a time-consuming and costly process. Certain matters
424B3
SCNI
Scinai Immunotherapeutics Ltd
2 Jan 24
Prospectus supplement
8:24am
. law is applicable to the claim. If U.S. law is found to be applicable, the content of applicable U.S. law must be proved as a fact by expert
F-1/A
SCNI
Scinai Immunotherapeutics Ltd
22 Dec 23
Registration statement (foreign) (amended)
9:11am
be proved as a fact by expert witnesses which can be a time-consuming and costly process. Certain matters of procedure may also be governed by Israeli law
F-1
SCNI
Scinai Immunotherapeutics Ltd
30 Oct 23
Registration statement (foreign)
4:59pm
. law is applicable to the claim. If U.S. law is found to be applicable, the content of applicable U.S. law must be proved as a fact by expert witnesses
424B5
SCNI
Scinai Immunotherapeutics Ltd
19 Sep 23
Prospectus supplement for primary offering
10:03am
as a fact by expert witnesses which can be a time-consuming and costly process. Certain matters of procedure may also be governed by Israeli law
424B2
55h786wn2kyr6i6tuac
28 Aug 23
Prospectus for primary offering
4:01pm
F-3
5lb6pz0ydcq o6j
18 Aug 23
Shelf registration (foreign)
4:16pm
10-K
58rdlm 20kl8tl
17 Apr 23
Annual report
4:06pm
6-K
EX-1.1
q96fe tpb
20 Dec 22
BiondVax Announces Closing of $8 Million Underwritten Public Offering
5:29pm
424B4
wr82xm9yb5eah qydzl
20 Dec 22
Prospectus supplement with pricing info
11:59am
F-1/A
EX-1.1
uss6xmhje
14 Dec 22
Registration statement (foreign) (amended)
4:45pm
F-1/A
5r7r 3azyu7ututm
12 Dec 22
Registration statement (foreign) (amended)
5:25pm
6-K
EX-99.1
ewu2v6ufgv
10 Nov 22
Current Report
5:28pm
F-1
ticyit djyxtnzs
29 Sep 22
Registration statement (foreign)
9:22am
6-K
EX-1.1
5oa ovwrjj
29 Dec 21
Report of Foreign Private Issuer
6:06am
424B5
875dr4ba2suc
28 Dec 21
Prospectus supplement for primary offering
5:20pm
424B5
50uk lt6anh2dbaq05
27 Dec 21
Prospectus supplement for primary offering
6:22am
6-K
EX-99.1
escn025cc9qfkpf l5dj
22 Nov 21
Report of Foreign Private Issuer
6:05am